Contrast material (CM) injectors are medical devices that inject CM into the body to make tissues more visible during various medical imaging examinations. These methods could involve magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), or magnetic resonance. Radiology, interventional cardiology, ambulatory surgery centers (ASCs), and diagnostic imaging facilities all around the world use CM injectors extensively.
The market value of contrast media injectors in 2021 was USD 2.15 billion and will reach USD 6.68 billion by 2030 at a 7.5% CAGR during 2021-2030.
Due to the sharp increase in patients suffering from malignant tumors and cardiovascular illnesses, the market for contrast media injectors is expanding at a rapid rate. The continuing quick growth of this market is anticipated to be accelerated by rising levels of installation of contrast media injectors in various radiology departments of healthcare facilities, evolving treatment paradigms, government backing, and improved healthcare & wellness awareness.
One of the major drivers driving the market’s expansion is the rise in popularity of minimally invasive (MI) medical procedures, which have a number of advantages, including smaller incisions, less postoperative pain, quicker recovery, and shorter hospital stays.
Additionally, cardiac imaging uses automated CM injectors more frequently to increase image quality and patient safety. Additionally, top players are concentrating on providing patients with customized CM doses utilizing data from an electronic medical record (EMR) or a picture archiving and communication system (PACS).
A significant factor hampering the growth of the global market for contrast media injectors over the forecast period is the high cost of the devices and their consumables and accessories. For example, MRI injectors are priced between US$ 35,000 and US$ 40,000, whereas CT injectors range from US$ 30,000 to US$ 40,000.
Additionally, there are several adverse reactions to contrast media, including nausea, vomiting, diarrhea, and stomach cramps (associated with barium sulphate contrast materials). Iodine-based contrast materials can cause headaches, flushing, and moderate skin rashes as side effects. Such adverse effects will hamper the market’s expansion.
Many makers of contrast media injectors are working to provide software that can analyze real-time data to access details like injection pressure, flow rate, contrast media type, and injection speed. This knowledge improves productivity and lowers error rates. Therefore, there is a huge potential for advancement for contrast media injectors in the future. Future opportunities are also fueled by the innovation of goods like power contrast injectors, MRI contrast injectors, MRI contrast media injectors, ct scan contrast media injectors, syringeless injectors, and syringe-free injection systems.
By Product, injector systems ruled the market in 2021, accounting for more than 61.33% of total sales. During CT, MRI, and angiography imaging treatments, contrast agents are injected into the bloodstream of patients, improving the visibility of the contrast of bodily fluids or structures.
By type, in 2021, single head injectors led the market and generated more than 44.44% of global revenue. Single head injectors for angiography, CT, and MRI are the most popular injectors. With these injectors, contrast media is delivered using just one syringe. In contrast to dual head injectors, which have two syringes and are typically utilized in CT systems, single head injectors are used in angiography.
By application, in 2021, radiology ruled the entire market with 47.39% of worldwide sales. Noninvasive imaging techniques like CT and MRI scans produce extremely detailed images in radiology. While MRI technology uses a magnetic field to make images inside a patient’s body, CT scanning uses X-ray equipment to construct a structure of cross-sectional images of the body to identify the origins of a medical illness, particularly in soft tissues.
By End-use, The hospital sector led the market with 68.07% of the global revenue in 2021. It is due to an increase in patients being admitted with neurological disorders, cardiovascular diseases, and cancer. Due to its numerous uses in radiology, interventional radiology, and interventional cardiology, hospitals are the main consumers of contrast media injectors.
In 2021, North America ruled the market and generated more than 38.75% of worldwide revenue. The region’s established healthcare facilities, easy access to cutting-edge technology, and strong demand for diagnostic procedures will increase inpatient examinations, driving market expansion. Additionally, due to the high prevalence of catastrophic accidents and chronic medical conditions, nations like the U.S. and Canada have seen an increase in hospital admissions in recent years.
- Guerbet Group
- Bayer Ag
- Nemoto Kyorindo Co., Ltd
- GE Company
- Bracco Imaging S.P.A
- Ulrich GmbH & Co. K.G.
- APOLLO RT Co. Ltd.
- Shenzhen Anke High-tech Co. Ltd
- Sino Medical-Device Technology Co., Ltd.
- Shenzen Seacrown Electromechanical Co Ltd.
- Medtron AG RT Co. Ltd.
The market value of contrast media injectors in 2021 was USD 2.15 billion and will reach USD 6.68 billion by 2030 at a 7.5% CAGR during 2021-2030. The rise in chronic disease prevalence, technological improvements, and the expanding need for minimally invasive surgical treatments contribute to the growth of the contrast media injectors market.